Goldman Sachs’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
Sell
-16,776
Closed -$8K 7468
2016
Q2
$8K Buy
+16,776
New +$26.9K ﹤0.01% 6895
2016
Q1
Sell
-16,006
Closed -$49K 7696
2015
Q4
$49K Buy
16,006
+4,342
+37% +$19.6K ﹤0.01% 6559
2015
Q3
$52K Buy
+11,664
New +$68.5K ﹤0.01% 6783
2015
Q2
Sell
-32,046
Closed -$287K 7721
2015
Q1
$287K Buy
32,046
+21,450
+202% +$172K ﹤0.01% 5693
2014
Q4
$60K Buy
+10,596
New +$55.4K ﹤0.01% 6758

Other funds holding EPRS

Goldman Sachs's EPRS Position: Q3 2016 in Review

Goldman Sachs sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2016, closing a stake of 16,776 shares — an estimated $8K sold.

Goldman Sachs first reported a position in EPRS in Q4 2014 and held it in 5 quarters. The position peaked at $287K in Q1 2015. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

  • Goldman Sachs reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2016 after selling out during the quarter.
  • Goldman Sachs sold 16,776 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2016, an estimated $8K.
  • Goldman Sachs first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q4 2014 and held it in 5 quarters.
  • Goldman Sachs's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $287K in Q1 2015.
  • 3 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2016.

Based on Goldman Sachs's 13F filing for Q3 2016, filed 14 Nov 2016.